Arbutus Biopharma Files 8-K on Operations and Financials
Ticker: ABUS · Form: 8-K · Filed: May 14, 2025 · CIK: 1447028
| Field | Detail |
|---|---|
| Company | Arbutus Biopharma Corp (ABUS) |
| Form Type | 8-K |
| Filed Date | May 14, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: operations, financials, reporting
TL;DR
Arbutus Biopharma dropped an 8-K on May 14th detailing financials and operations.
AI Summary
Arbutus Biopharma Corporation filed an 8-K on May 14, 2025, reporting on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company was formerly known as Tekmira Pharmaceuticals Corp.
Why It Matters
This 8-K filing provides an update on Arbutus Biopharma's financial status and operational results, which is crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting operational and financial information, not indicating any immediate significant risks.
Key Players & Entities
- Arbutus Biopharma Corporation (company) — Registrant
- Tekmira Pharmaceuticals Corp (company) — Former company name
- May 14, 2025 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Arbutus Biopharma Corporation's results of operations and financial condition, and to include financial statements and exhibits.
When was this 8-K report filed?
This 8-K report was filed on May 14, 2025.
What was Arbutus Biopharma Corporation's former name?
Arbutus Biopharma Corporation was formerly known as Tekmira Pharmaceuticals Corp.
What is the principal executive office address for Arbutus Biopharma Corporation?
The principal executive office address is 701 Veterans Circle, Warminster, Pennsylvania 18974.
In which jurisdiction was Arbutus Biopharma Corporation incorporated?
Arbutus Biopharma Corporation was incorporated in British Columbia, Canada.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 14, 2025 regarding Arbutus Biopharma Corp (ABUS).